World GI 2017 Media Alert: Coming Soon – World’s Largest Gastrointestinal Cancer Congress

  • Date: 15 Jun 2017

Lugano, Barcelona – Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 19th ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 28 June to 1 July 2017.

The World GI Congress is the premier global event in the field – encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and rare tumours.

Colorectal and stomach cancers are among the most common cancers in the world.1 Many unmet needs exist in certain cancers such as pancreatic, liver and gall bladder cancers, which are among the most common causes of death worldwide.2

There are currently hundreds of ongoing studies in the field of GI malignancies and the ESMO 19th World Congress on Gastrointestinal Cancer will present the latest research with a potential to change outcomes for patients worldwide.

Scientific Programme

Over 425 abstracts were accepted for presentation at the ESMO 19th World Congress on Gastrointestinal Cancer, including research on:

  • Liquid biopsies
  • The role of the microbiome in cancer medicine
  • Immune mechanisms and immune therapy in GI cancer
  • New drugs
  • Molecular markers

Further information on the congress agenda can be found here. Abstracts presented at World GI Congress will be published on 28 June in a supplement of Annals of Oncology.

Embargo information

Oral and late breaking abstracts selected by the Scientific Committee for presentation at World GI Congress are embargoed until the end of the scientific session during which they are presented. Oral abstracts scheduled for presentation include:

Wednesday, 28 June 2017

  • PEGPH20 Improves PFS in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Phase 2 Study in Combination With nab-Paclitaxel/Gemcitabine +. Andrew Hendifar, et al., O-003
  • Tumor Hyaluronan May Predict Benefit from PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA). Andrew Hendifar, et al., O-028 

Thursday, 29 June 2017

  • Nivolumab Monotherapy in Patients with Advanced Gastric of Gastroesophageal Junction (GEJ) Cancer and 2 or More Prior Treatment Regimens: Sub-Analysis of the CheckMate 032 Study. Patrick Ott, et al., O-007
  • Efficacy and Safety of Nivolumab in Patients with Advanced Hepatocellular Carcinoma Analyzed by Patient Age: A Sub-Analysis of the CheckMate 040 Study. Ignacio Melero, et al., O-008
  • Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. Jordi Bruix, et al., O-009

Friday, 30 June 2017

  • Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Aparna Parikh, et al., O-001
  • Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC). Enrique Sanz-García, et al., O-010
  • RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC). Filippo Pietrantonio, et al., O-011
  • Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial. Eric Van Cutsem, et al., O-012
  • The prognostic impact of primary tumor location in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis. Yuichi Goto, et al., O-013
  • Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status. Julien Taieb, et al., O-015
  • Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Stephanie Reyes, et al., O-021
  • Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia. Mark Eccleston, et al., O-022
  • Mediterranean diet components are negatively associated with advanced colorectal polyps in a population-based case-control study. Naomi Fliss Isakov, et al., O-023
  • Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations? Garry Mahon, et al., O-024

Saturday, 1 July 2017

  • Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall survival. Dominik Modest et al., O-029
  • Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study. Dominik Modest, et al., O-026
  • Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. Guy van Hazel, et al., O-027

The World GI Congress will take place in the The International Convention Center of Barcelona (CCIB) and is organized by Imedex.

-END-

Notes for Editors

References

1 International Agency for Research on Cancer (IARC), Globocan 2012. Stomach and Colorectal Cancers, Estimated Incidence, Mortality and Prevalence Worldwide in 2012.

Colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second in women (614,000 cases, 9.2% of the total) worldwide. Almost 55% of the cases occur in more developed regions

Almost one million new cases of stomach cancer were estimated to have occurred in 2012 (952,000 cases, 6.8% of the total), making it the fifth most common malignancy in the world, after cancers of the lung, breast, colorectum and prostate.

2 Cancer Research UK 

Media Registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO 2017 Media Policy.

Press members may register using this link.

Media registration in advance is strongly recommended.

A Press Working Room will be available to registered journalists.

Meeting venue

The International Convention Center of Barcelona (CCIB)
Rambla de Prim 1-17
08019 Barcelona, Spain

For more information, please contact

ESMO Press Office
media@esmo.org
Tel: +41 (0)91 973 19 04